TruBridge, Inc. disclosed errors in its financial statements for 2023 and 2024, leading to a delayed annual report and a 10.5% drop in its stock price. The errors involved revenue recognition, contract costs, stock-based compensation, and software development expenses. Rosen Law Firm is investigating and preparing a class action lawsuit to recover losses for shareholders who bought TruBridge securities. Investors may join the suit without upfront fees through a contingency arrangement.
Rosen Law Firm is investigating potential securities claims against Barclays PLC following reports that Barclays may have provided misleading business information related to its exposure to UK mortgage lender Market Financial Solutions Ltd (MFS), whi...
MSC Income Fund (MSIF) has been upgraded to a buy rating as it currently trades at a 24% discount to its net asset value (NAV). The fund offers a 10.9% yield supported by a diversified portfolio of primarily first-lien, floating-rate assets, with imp...
XRP is trading tightly around $1.39 within a $1.37–$1.42 range after a prolonged downtrend, with AI models from OpenAI, Anthropic, and xAI indicating a bearish-leaning consolidation. Key support at $1.37 and resistance at $1.42 will likely determine ...
Cameron Dawson highlights that semiconductor stocks now make up 18% of the S&P 500, more than double their weight during the tech bubble peak, driven mainly by giants like NVIDIA. This concentration extends to value and emerging market indexes, with ...
Rapid Micro Biosystems announced an underwritten offering priced at $9.8 million, selling shares and warrants that could raise up to $32 million if all warrants are exercised. Investors include Bain Capital Life Sciences and Armistice Capital. The of...
